Beckley Psytech, a company dedicated to addressing neurological and psychiatric disorders, agreed to acquire Eleusis Therapeutics, a clinical-stage life science company. Financial terms were not disclosed. “This is a hugely exciting acquisition for Beckley Psytech, and we are delighted to add Eleusis’ innovative products to our portfolio of differentiated clinical assets. Our highly focused pipeline, now strengthened with a Phase 1 ready, next generation, short-acting psychedelic, will deliver multiple value inflection points over the next 18 months. We are also very pleased to welcome the Eleusis team to Beckley Psytech and we look forward to benefiting from their exceptional knowledge and experience. With a cash runway for operations extending into 2025, this acquisition reinforces Beckley Psytech’s position as a market leader in the development of psychedelic therapies," Cosmo Feilding Mellen, Beckley Psytech CEO.